Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Top Cited Papers
- 1 January 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 21 (1), 44-59
- https://doi.org/10.1016/S1470-2045(19)30689-8
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Survival with metastatic breast cancer based on initial presentation, de novo versus relapsedBreast Cancer Research and Treatment, 2016
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 2016
- PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomasHuman Pathology, 2015
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- Prognostic and predictive value of PDL1 expression in breast cancerOncotarget, 2014
- Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World ScenarioThe Oncologist, 2014
- PD-L1 Expression in Triple-Negative Breast CancerCancer Immunology Research, 2014
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2013
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast CancerJournal of Clinical Oncology, 2010
- The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic FactorsNeoplasia, 2006